Compass Pathways may be the first to benefit from an accelerated approval process.

Compass Pathways stock surged Monday after President Donald Trump signed an executive order tied to psychedelic drugs.

Compass Pathways (CMPS) shares printed a new year-to-date high on April 20 after President Donald Trump signed a landmark ...

Donald Trump's order on psychedelic drugs sent shares of companies in the space surging. RFK Jr and Joe Rogan were present at ...

COMPASS Pathways (CMPS) stock jumped 25% after Trump's executive order on psychedelic research. Positive Phase 3 data boosts ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The field of psychedelic medicine is relatively new, and because of this, certain investors consider it to be loaded with potential. That's why even minor events in companies specializing in this can ...

Compass Pathways plc (NASDAQ:CMPS) released data from the Phase 3 COMP005 trial, the first of two Phase 3 trials evaluating COMP360 for treatment-resistant depression (TRD). Despite meeting the ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Shares of Compass Pathways fell after the company recorded a wider-than-expected fourth-quarter loss. Shares were down 3.3% to $5.17 in Tuesday morning trading. The stock is up 66% over the past year.

President Trump's executive order is giving psychedelic stocks a boost. These companies are leaders in the industry.

Wall Street is currently pivoting toward high-growth biotech plays as federal support accelerates a revolution in alternative ...